Global Phenylketonuria Market to Reach USD 1,230.05 Million by 2030 | CAGR of 5.2%
Category : Healthcare | Published Date : Oct 2024 | Type : Press Release
Phenylketonuria Market Scope & Overview:
In the newly published report Consegic Business Intelligence states that the Phenylketonuria Market size was valued at USD 820.57 Million in 2022 and is projected to reach USD 1,230.05 Million by 2030, growing at a CAGR of 5.2% from 2023 to 2030. Phenylketonuria (PKU) is a rare genetic disorder caused by a deficiency in the PAH gene, leading to the buildup of phenylalanine in the blood. This condition, if untreated, results in severe neurological issues. PKU management involves dietary restrictions and the use of specialized supplements and drugs to prevent phenylalanine accumulation.
The report comprises the Phenylketonuria Market Share, Size & Industry Analysis, By Type (Hyperphenylalaninemia, Mild PKU, Moderate and Variant, and Classic PKU), Product Type (Drugs (Kuvan, Pegavaliase, and Others), Nutritional Supplements, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2023-2030.
The report contains detailed information on Phenylketonuria Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The increasing prevalence of phenylketonuria and advancements in genomics are key drivers of market growth. Additionally, increased R&D funding in bioinformatics presents growth opportunities.
Segmental Analysis :
Based on type, the market is segmented into hyperphenylalaninemia, mild PKU, moderate and variant, and classic PKU.
- Classic PKU held the largest market share in 2022, attributed to its high prevalence and severe nature, which demands lifelong treatment and management.
Based on product type, the market includes drugs, nutritional supplements, and others.
- Nutritional supplements dominated the market in 2022 due to their ease of use and fewer side effects, supporting dietary management for PKU patients.
Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.
- Hospital pharmacies held the largest share in 2022, driven by the availability of specialized treatments for PKU in hospitals.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America led the market in 2022, supported by the high prevalence of PKU in the U.S. and the availability of advanced treatment options.
- Europe is expected to grow rapidly due to the high incidence of PKU and expanding medical resources in countries like Ireland and Turkey.
| Report Attributes | Report Details |
| Study Timeline | 2017-2030 |
| Market Size in 2031 | USD 1,230.05 Million |
| CAGR (2024-2031) | 5.2% |
| By Type | Hyperphenylalaninemia, Mild PKU, Moderate and Variant, Classic PKU |
| By Product Type | Drugs (Kuvan, Pegavaliase, Others), Nutritional Supplements, Others |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Phenylketonuria Industry:
- Cambrooke Therapeutics
- American Gene Technologies International, Inc.
- BioMarin Pharmaceutical, Inc.
- PTC Therapeutics
- Relief Therapeutics Holding SA
- Codexis, Inc.
- Agios Pharmaceuticals Inc
- Castle Crek Biosciences, Inc.
- Synlogic
- Pristine Organics
- Galen Pharma
Recent Industry Developments :
- In October 2022, Relief Therapeutics launched PKU GOLIKE, a medical food product for dietary management of phenylketonuria (PKU).
- In October 2020, BioMarin Pharmaceutical received FDA approval for an increased maximum dose of Palynziq for PKU treatment.
